LRMR

MKT CAP:$386M

Larimar Therapeutics, Inc.

Market Cap

$386M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$4.50+$1.03 (+29.68%)

Apr 23, 2026

Company Details

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1...

CEO

Carole S. Ben-Maimon

IPO Date

Jun 19, 2014

Website

www.larimartx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$166M

EPS (Diluted)

-$2.21

Free Cash Flow

-$113M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

Apr 29, 2026

PENDING

FY 2025

Mar 19, 2026

$0EPS -$2.27

Q4 2025

Mar 19, 2026

$0EPS -$0.73

Q3 2025

Nov 5, 2025

$0EPS -$0.61

Q2 2025

Aug 14, 2025

$0EPS -$0.41

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$9M
Q2 22	$0	$0	-$9M
Q3 22	$0	$0	-$9M
Q4 22	$0	$0	-$10M
Q1 23	$0	$0	-$8M
Q2 23	$0	$0	-$10M
Q3 23	$0	$0	-$10M
Q4 23	$0	-$81.0K	-$14M
Q1 24	$0	-$80.0K	-$17M
Q2 24	$0	$0	-$25M
Q3 24	$0	$0	-$18M
Q4 24	$0	$0	-$31M
Q1 25	$0	$0	-$31M
Q2 25	$0	$0	-$28M
Q3 25	$0	$0	-$49M
Q4 25	$0	-$87.0K	-$64M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$8M	-$8M
Q2 22	-$7M	-$8M
Q3 22	-$6M	-$6M
Q4 22	-$7M	-$7M
Q1 23	-$8M	-$8M
Q2 23	-$7M	-$7M
Q3 23	-$9M	-$9M
Q4 23	-$9M	-$10M
Q1 24	-$10M	-$10M
Q2 24	-$14M	-$14M
Q3 24	-$25M	-$25M
Q4 24	-$22M	-$22M
Q1 25	-$27M	-$27M
Q2 25	-$19M	-$19M
Q3 25	-$29M	-$29M
Q4 25	-$39M	-$39M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$100.0K
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$164.0K
Q1 24	$0
Q2 24	$274.0K
Q3 24	$62.0K
Q4 24	$179.0K
Q1 25	$49.0K
Q2 25	$19.0K
Q3 25	$23.0K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-26.6%
Q2 22	—	-30.7%
Q3 22	—	-49.1%
Q4 22	—	+14.9%
Q1 23	—	-14.1%
Q2 23	—	+10.7%
Q3 23	—	+21.4%
Q4 23	—	+35.7%
Q1 24	—	+119.1%
Q2 24	—	+155.7%
Q3 24	—	+76.7%
Q4 24	—	+121.0%
Q1 25	—	+86.4%
Q2 25	—	+13.0%
Q3 25	—	+171.0%
Q4 25	—	+104.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$2M	—
Q3 22	$0	—
Q4 22	$2M	—
Q1 23	$2M	—
Q2 23	$2M	—
Q3 23	$0	—
Q4 23	$2M	—
Q1 24	$2M	—
Q2 24	$2M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$2M	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$6M	$3M	—	—
Q2 22	$6M	$3M	—	—
Q3 22	$6M	$3M	—	—
Q4 22	$7M	$3M	—	—
Q1 23	$5M	$3M	—	—
Q2 23	$6M	$4M	—	—
Q3 23	$7M	$4M	—	—
Q4 23	$11M	$4M	—	—
Q1 24	$13M	$4M	—	—
Q2 24	$20M	$5M	—	—
Q3 24	$14M	$4M	—	—
Q4 24	$27M	$5M	—	—
Q1 25	$27M	$5M	—	—
Q2 25	$23M	$4M	—	—
Q3 25	$45M	$5M	$100.0K	—
Q4 25	$59M	—	—	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$63M	$0	$63M
Q2 22	$20M	$35M	$55M
Q3 22	$86M	$39M	$125M
Q4 22	$27M	$92M	$118M
Q1 23	$112M	$0	$112M
Q2 23	$94M	$10M	$104M
Q3 23	$39M	$57M	$96M
Q4 23	$27M	$60M	$87M
Q1 24	$110M	$117M	$227M
Q2 24	$32M	$194M	$226M
Q3 24	$35M	$169M	$204M
Q4 24	$33M	$150M	$183M
Q1 25	$21M	$136M	$158M
Q2 25	$21M	$118M	$139M
Q3 25	$90M	$85M	$175M
Q4 25	$85M	$51M	$137M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	18M	0.0%	+14.6%
Q2 22	18M	0.0%	+14.6%
Q3 22	22M	+21.2%	+21.5%
Q4 22	24M	+7.9%	+30.8%
Q1 23	44M	+82.9%	+139.4%
Q2 23	44M	0.0%	+139.4%
Q3 23	44M	+0.0%	+97.5%
Q4 23	44M	+0.0%	+83.0%
Q1 24	54M	+22.0%	+22.0%
Q2 24	64M	+19.1%	+45.3%
Q3 24	64M	+0.0%	+45.3%
Q4 24	64M	+0.0%	+45.3%
Q1 25	64M	+0.2%	+19.4%
Q2 25	64M	+0.1%	+0.4%
Q3 25	78M	+22.3%	+22.8%
Q4 25	85M	+8.8%	+33.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	31
Q2 22	$0	31
Q3 22	$0	31
Q4 22	$0	26
Q1 23	$0	26
Q2 23	$0	26
Q3 23	$0	26
Q4 23	$0	42
Q1 24	$0	42
Q2 24	$0	42
Q3 24	$0	42
Q4 24	$0	65
Q1 25	$0	65
Q2 25	$0	65
Q3 25	$0	65
Q4 25	$0	20K

Revenue / Employee